Cobalt Keys LLC, an email marketing firm, is one of the only organizations in existence to be a certified partner with both Clay.com and Instantly.ai. These partnerships allow Cobalt Keys LLC to leverage results with in-depth analytics and streamlined communication workflows.
By joining forces with Clay.com, Cobalt Keys LLC gains access to advanced data analytics and customer interaction tools. These tools help the company create marketing campaigns that engage customers more effectively. The strong analytics from Clay.com will assist Cobalt Keys LLC in offering data-supported results, an essential part of today’s digital landscape.
Similarly, their certification with Instantly.ai gives Cobalt Keys LLC more power in automated communication. Instantly.ai is known for its expertise in email marketing automation, which helps maintain clear and efficient communication with customers. By utilizing these tools, Cobalt Keys LLC can develop campaigns that build strong customer relationships while simplifying communication efforts. More details on their AI solutions for improving marketing strategies can be discovered through their AI Solutions services.
This partnership highlights the growing trend towards Omni Channel Marketing, where businesses seek to create a consistent experience across many platforms. As customers engage with brands in various ways, delivering a seamless experience becomes increasingly crucial. By holding dual certification, Cobalt Keys LLC strives to meet these demands, helping clients enhance their brand visibility through different digital channels. Their dedication to creating robust online assets to boost brand presence can be explored in their Brand Exposure services.
A spokesperson for Cobalt Keys LLC, shares their thoughts on these partnerships, stating, “Our collaboration with Clay.com and Instantly.ai is proof of our commitment to lead with innovation. These partnerships allow us to boost our capabilities and give our clients the most effective marketing strategies.”
Being certified with these leading platforms means Cobalt Keys LLC remains competitive in the ever-changing digital marketing world. As the industry shifts, keeping up with new technologies guarantees effective marketing. These partnerships bring benefits to Cobalt Keys LLC clients by broadening their reach and improving customer engagement.
The spokesperson adds, “The certification with both Clay.com and Instantly.ai highlights our commitment to delivering results. With access to cutting-edge technologies, our clients can expect more efficient campaigns and better engagement.”
By integrating tools from Clay.com and Instantly.ai, Cobalt Keys LLC continues to set standards in comprehensive marketing strategies. Discover more about their comprehensive media engagement techniques in their Media Coverage services.
Cobalt Keys LLC also offers organic traffic generation services, media coverage services, AI automation, email marketing, business growth, development, and scaling. The company continues to expand its offerings and improve the services offered to clients to achieve the best brand visibility.
By maintaining a forward-thinking approach, Cobalt Keys LLC aims to meet market demands today while also predicting future trends in marketing, technology, and consumer behavior.
Cobalt Keys LLC focuses its operations on innovation and adaptability. These certifications allow the company to give clients solutions that integrate top technologies from Clay.com and automated processes of Instantly.ai.
Through these certifications and a broad range of marketing solutions, Cobalt Keys LLC positions itself as a partner for businesses looking to navigate a competitive digital environment. By combining innovation, adaptability, and strategic expertise, the company works with clients to achieve sustainable growth while building lasting connections with audiences.
###
For more information about Cobalt Keys LLC, contact the company here:
Cobalt Keys LLC Cynthia Hoyt (888) 262-2589 contact@cobaltkeys.com 220 EMERALD VISTA WAY #670 LAS VEGAS NV 89144
Investment will accelerate GEOH’s expansion as a leading end-to-end software and services platform for home care agencies.
INDIANAPOLIS, IN / ACCESS Newswire / September 9, 2025 / GEOH, one of the fastest-growing providers of practice management software and services for home care agencies, has raised over $30 million from Council Capital and affiliates. Council Capital is a healthcare-focused private equity firm with deep expertise in software and revenue cycle management.
Council Capital joins existing investors Boomerang Ventures, First Leaf Capital, and VisionTech Partners and brings over 25 years of experience and a proven track record of partnering with growing healthcare-technology companies.
“We’re thrilled to partner with Council Capital to fuel the next chapter of GEOH’s growth,” said Tom Bumgardner, CEO of GEOH. “Their experience in our space, deep understanding of practice management, revenue cycle management, and strong investment team make them an ideal partner. We’re incredibly excited about what’s ahead.”
“We have been extremely impressed with GEOH and it’s ability to support home care agencies by simplifying billing and regulatory compliance and ensuring they capture every dollar they’ve earned,” said Kevin Fahey, Partner at Council Capital. “GEOH’s platform offers user-friendly, fully integrated solution that reduced administrative burden, improves staff efficiency, and drives higher collections.)” We are looking forward to working with Tom and the entire management team to continue their mission of helping Home Care agencies increase cash flows.” “
GEOH’s hybrid software +service approach has developed into the premier end-to-end solution for home care agencies to manage their workforce, deliver care to their clients, and get paid for the essential services they provide. GEOH’s revenue cycle management and executive services have helped agencies collect over $275 million to date. The Company has doubled its revenue every year for the last three years.
“From the beginning, we believed in the team’s vision and ability to transform home care. Council Capital’s investment validates that conviction and sets the stage for even greater impact. We’re excited to continue supporting this team as they scale one of the most innovative platforms in the market.” said Oscar Moralez, Managing Partner at Boomerang Ventures.
About GEOH
GEOH helps owners and managers of Medicaid home care and health agencies run profitable, problem-free practices. With an end-to-end software platform and white-glove services, GEOH empowers agencies to grow efficiently while delivering exceptional care. The result? Businesses that thrive, teams who love coming to work, and the ability to double or even quadruple revenue with confidence. For more information, visit geoh.app.
About Council Capital
Council Capital is a healthcare-focused private equity firm based in Nashville, Tennessee. Now investing out of its fourth fund, Council aspires to partner with high-growth healthcare companies to achieve strong investment returns by investing in businesses that make healthcare better. The firm has deep experience in scaling software, revenue cycle management, and service models in healthcare and brings a powerful network of industry leaders to each of its portfolio companies. For more information, visit councilcapital.com.
Media Contact: Audra Wait / Wait & Co. On behalf of GEOH and Boomerang Ventures 615-504-8812 audra@waitandco.com
Praised by The Wall Street Journal for how it “distills the presidents’ stories into guidelines for the rest of us,” the book is both a captivating history and a smart guide to how money shapes lives – even in the Oval Office. Air Mail called it “a charming history of American presidents’ financial affairs,” cementing its place as one of the most entertaining and enlightening presidential reads in recent years.
In this fascinating, non-political exploration of presidential history, Gorman takes readers behind the scenes of America’s highest office to reveal how its leaders earned, spent, saved – and sometimes squandered – their fortunes.
“This isn’t just a history book,” Gorman explains. “It’s a non-political look at the personal finances of our presidents and how some of them built wealth and some of them didn’t. Money is hard – it’s hard to build wealth – and what this book shows is that even the most powerful men in the country have struggled with it too.”
Drawing on her career as a tax attorney and founder of Chequers Financial Management, Gorman brings a wealth advisor’s perspective to presidential history. Her research took her deep into the National Archives and presidential libraries, reviewing original documents from George Washington’s Revolutionary War balance sheets to Franklin Roosevelt’s life insurance applications. “Money humanizes these figures we usually see as carved in marble,” she says. “It makes them relatable.”
All the Presidents’ Money is as insightful as it is entertaining, peppered with surprising anecdotes – including John F. Kennedy instructing White House butlers not to open new champagne until the old bottles were finished – reminding readers that even presidents worried about party budgets.
Beyond the anecdotes, Gorman’s work invites a bigger reflection on money, legacy, and values. “One of my clients, a retired CFO, told me, ‘If you take out the parts about the presidents, you have your firm’s entire philosophy on wealth.’ That really resonated with me,” she shares. “What I hope readers take away is that no matter how successful you are, we all face money challenges – and it’s okay to struggle as long as you learn, pivot, and keep going.”
The paperback edition arrives at a moment when conversations around wealth and the American Dream feel especially relevant. “The dream is still there,” Gorman reminds us. “But sometimes harder to access. That’s why financial literacy and thoughtful conversations about money matter more than ever.”
About the Author
Megan Gorman is the founder of Chequers Financial Management, a Forbes Top 100 wealth management firm. A former tax attorney who began her career at Goldman Sachs, she specializes in working with high-net-worth and ultra-high-net-worth individuals and families. Gorman is a frequent contributor to major media outlets, including The Wall Street Journal and Forbes, and is a sought-after speaker on wealth management and financial literacy.
Alliance Brings Advanced Telehealth and Workforce Solutions to Rural Communities
NEW YORK, NY / ACCESS Newswire / September 9, 2025 / Equum Medical, a leading provider of telehealth-enabled clinical services, and the National Rural Health Association (NRHA) have announced a renewed strategic partnership that will carry their collaboration through five years. This continued alliance – which affirms Equum as NRHA’s Gold Partner – is focused on expanding access to care for rural hospitals nationwide through innovative telehealth and workforce solutions. The partnership comes at a critical juncture in rural health, as regulatory reforms and care delivery transformations accelerate efforts to improve health access in underserved communities.
A Pivotal time for Rural Health
The renewal comes at a time where nearly 46% of rural hospitals currently operate at a loss, and 432 facilities are deemed vulnerable to closure. These financial strains, coupled with persistent workforce shortages, have created expanding “care deserts” in many rural regions – leaving gaps in vital services like emergency care, and specialty medicine. Telehealth has emerged as a crucial lifeline to help bridge these gaps. By leveraging virtual care platforms, patients in remote areas can receive timely consultations and critical interventions from specialists without traveling long distances. In fact, telehealth utilization across the U.S. has stabilized at roughly ten times pre-pandemic levels, underscoring the technology’s permanent role in care delivery and its immense promise for rural hospitals striving to keep care local.
“Telehealth has fundamentally changed how we deliver care in rural areas, and extending this partnership ensures we can continue that positive transformation for years to come,” said Brock Slabach, MPH, FACHE, Chief Operating Officer of NRHA. “Rural hospitals are navigating unprecedented challenges – from workforce shortages to financial pressures, and Equum Medical’s support gives them the tools and specialist expertise to overcome resource constraints. By keeping more care local, we’re not only improving patient outcomes but also strengthening the viability of our rural health systems.”
Value of Partnership
Since first joining NRHA’s partner network in 2022, Equum Medical has collaborated with NRHA on multiple initiatives to bolster rural care delivery. Last year, Equum launched a Collaborative Shared Services Program, a novel model developed in response to NRHA member needs, that allows groups of critical access and community hospitals to share telehealth services and specialist coverage as a unified network. This peer-driven approach helps reduce patient outmigration by enabling even the smallest hospitals to offer high-acuity care locally, forming “virtual regional alliances” that extend from emergency tele-neurology to ICU oversight. Equum’s telehealth offerings now span emergency medicine, critical care, behavioral health, virtual nursing, remote patient monitoring and more, giving rural facilities on-demand access to a broad spectrum of expertise that was often out of reach. Through its national Virtual Care Collaboration Center, Equum has already delivered over 2 million hours of virtual care in the past year – a volume expected to double in the near term amid surging demand for telehealth services.
Reach and Impact
The impact of these telehealth interventions has been both measurable and meaningful. Rural hospitals leveraging Equum’s services are able to treat more patients in place, avoiding unnecessary transfers to distant facilities. For example, tele-neurology consults now allow stroke patients to receive clot-busting therapy (tPA) at their local hospital, significantly improving survival rates and recovery times. Virtual specialist support in areas like critical care, cardiology, and infectious disease enables rural clinicians to co-manage complex cases instead of defaulting to transfers. By keeping patients closer to home, hospitals provide a smoother care experience and enhance patient safety and satisfaction. This also yields major operational benefits – each patient retained locally boosts bed utilization and can generate $12-$14,000 in revenue for a critical access hospital and each avoided transfer saves roughly $2,500 in transport expenses. These outcomes underscore why telehealth adoption is accelerating in rural areas and why innovative care models are vital to rural hospitals’ future.
“Equum Medical was founded to address the unique challenges of rural hospitals, and our mission has always been to keep patients and care accessible in their communities,” said Dr. Corey Scurlock, MD, MBA, CEO and Founder of Equum Medical. “Over the past few years, we’ve seen firsthand how telehealth can save lives and strengthen rural hospitals – from providing ICU coverage that prevented patient transfers to deploying virtual specialists who delivered stroke treatments in time. Renewing our collaboration with NRHA is a commitment to accelerate these successes on a national scale. In the coming five years, we will broaden telehealth adoption even further, introduce new services like tele-hospitalists to support inpatient care, and help rural providers navigate every regulatory change and workforce challenge. Together with NRHA, we are confident we can drive transformative change in rural health delivery, ensuring that geography is no longer a barrier to high-quality care.”
This renewed partnership solidifies Equum Medical’s role as a key resource for NRHA’s 21,000 members across all 50 states. Equum will continue as a Gold-level annual sponsor, providing education, advocacy, and shared expertise to help rural providers adapt and thrive. With telehealth poised to play an even larger role in bridging rural care gaps, the time is now to embrace this technology fully and invest in the health of our rural communities. This extended Equum-NRHA alliance is positioned to drive significant improvements in access, quality and financial stability for rural hospitals in the years ahead.
About Equum Medical
Equum Medical is a nationally recognized leader in telehealth-enabled clinical services, helping hospitals and health systems enhance care delivery and serve more patients while achieving positive clinical, operational, and financial outcomes. Equum works with providers large and small – urban and rural – with a focus on ensuring medically underserved communities have access to world-class specialist expertise. Founded over a decade ago by physicians committed to improving rural health, Equum offers a flexible, hybrid-care approach and a wide menu of multi-specialty, critical care, virtual nursing, and other services tailored to the needs of critical access and community hospitals. Equum’s mission is to enhance access to care, improve patient outcomes, and support healthcare providers through innovative, technology-driven solutions. For more information, visit EquumMedical.com.
About the National Rural Health Association (NRHA)
NRHA is a nonprofit organization working to improve the health and well-being of rural Americans and to provide leadership on rural health issues through advocacy, communications, education, and research. The Association’s membership comprises approximately 26,000 individuals and organizations across all 50 states, all dedicated to addressing the unique healthcare challenges facing rural communities. NRHA brings together rural health care providers, policymakers, and stakeholders to develop and promote innovative solutions and policies that ensure equitable, high-quality, and affordable care for rural populations. For more information, visit RuralHealth.us.
The popular series profiling business innovators on Fox Business, Bloomberg, and A&E builds on its 13 years of success with a companion audio show offering a deeper dive into the stories of visionary entrepreneurs and trend-defining companies.
LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 9, 2025 / “Trending Today,” the acclaimed TV series airing on Fox Business, Bloomberg, and A&E, announces a new podcast as a “sister show” to the long-running TV series. The audio show offers listeners a more relaxed yet in-depth exploration of the influential business leaders behind brands like Samsung, TurboTenant, and Tommy Bahama, and Tori Dunlap @herfirst100k, a New York Times best-selling author and host of the #1 money podcast for women, Financial Feminist.
“Trending Today” is the go-to series for an insider’s look into the entrepreneurial spirit driving some of the biggest global brands and personalities. “Trending Today” has received multiple Telly awards and recognition from the Los Angeles Film Awards, the Vegas Television and Movie Awards, and the Lonely Wolf Film Festival.
“We’re thrilled to expand the ‘Trending Today’ brand with the launch of ‘The Trending Today Podcast,’” said Executive Producer Liz Plummer. “Our television show has always given audiences a first look at innovators and entrepreneurs shaping the future, and now the podcast offers our guests a longer format to dive deeper into their stories, insights, and vision. It’s an exciting new way for us to give these leaders the platform they deserve.”
In Season 1, the “Trending Today Podcast” will highlight exciting stores from brands like Samsung, TurboTenant, Tommy Bahama, Jiffy, Ravin Consultants, Vivid Seats, SYNT, YNG Aesthetics and The House of She, Financial Feminist and more.
Listeners will hear firsthand from the executives behind some of the most prominent brands featured on the show, sharing valuable lessons from their journeys. Excerpts highlight the intense work and dedication behind the scenes that builds incredible brands, and conversations center around what it takes to reach seemingly overnight success.
In an episode exploring the live event space, Stan Chia, CEO of Vivid Seats, North America’s largest online ticketing platform, shared his insights consumer trust: “When I think about the live event space and what people are looking for, I think people are always looking for a platform that is secure and one you can trust.”
Brad Leavitt, CEO and founder of A Finer Touch Construction, a major player in luxury custom homes, emphasizes the importance of teamwork and collaboration: “Surrounding yourself with great people is really the key. That’s part of the hard work.”
Doug Wood, CEO of Tommy Bahama, discusses the importance of personal accountability and learning from mistakes: “Some of the worst decisions that are made are the ones you choose, that you didn’t make, and you just let something happen.”
Other notable episodes include:
From Prison to Purpose: Scott Curley’s Redemption Story
Financial Feminism with Tori Dunlap
Skin & Soul with Bree Gionta and Amy Cunningham
The “Trending Today Podcast” is growing quickly and new episodes are available on all major podcast platforms, including Spotify, Apple Podcasts, Podbean, and Overcast.
Subscribe to the podcast across your favorite listening platform, rate and review to support the show, and share guest or topic suggestions to shape future episodes. To learn more about “Trending Today,” visit https://trendingtoday.com/.
About “Trending Today”
“Trending Today,” the acclaimed television series airing on A&E, Bloomberg, and Fox Business, captures the entrepreneurial ambition that drives innovation around the world. Each episode highlights the latest technologies, market trends, and groundbreaking ideas through a thoughtfully selected lineup of inventors, innovators, and thought leaders. Crossing a wide range of industries, including consumer products, luxury lifestyles, health, and technology, “Trending Today” features companies and people who are pushing boundaries and redefining excellence. To learn more, visit www.trendingtoday.com.
Proprietary safety intelligence creates dual value: faster therapeutic development and biodefense.
LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 9, 2025 / Lunai Bioworks Inc. (NASDAQ:RENB), an AI-powered drug discovery and biodefense company, today announced the launch of a transformer-based platform that embeds biological risk intelligence directly into large language model (LLM) pipelines. This breakthrough uses virtual chemical screening to identify novel compounds as being potentially toxic, expediting therapeutic discovery and development. Through its application, this platform also addresses a growing security concern, the misuse of generative AI in designing hazardous biological or chemical compounds.
With generative AI rapidly transforming healthcare and biotech, investors and regulators are increasingly focused on the dual-use challenge: the same algorithms that discover new medicines could also be exploited to create novel toxins. Lunai Bioworks’ solution embeds a proprietary neurotoxicity intelligence layer into LLM workflows, ensuring safety while preserving innovation.
“This is all about understanding and predicting risk,” said Dr. Gabe Musso, Chief Scientific Officer of Lunai Bioworks’ wholly owned subsidiary Biosymetrics Inc. “Our platform accelerates the discovery of safe, effective therapeutics, with the added benefit of being able to safeguard against the creation of novel chemical threats. That’s a major differentiator for our partners.”
Key investment highlights:
Exclusive Data Advantage: Powered by our large in vivo neurotoxicity datasets, collected from thousands of zebrafish-based assays, offering biological realism unmatched by public or in silico-only resources.
Defensible Technology: Transformer-based safety intelligence acts as a real-time safeguard within generative AI pipelines, creating a strong moat in a high-growth sector.
Massive Market Opportunity: Supports dual markets – multi-billion-dollar drug discovery AI and biodefense AI – both undergoing rapid expansion driven by government, pharma, and biotech demand.
Alignment with Global Priorities: Addresses urgent calls from regulators, governments, and AI safety organizations for robust safeguards against AI-enabled biothreats.
Scalable Partnerships: Positioned for integration with pharmaceutical pipelines, biotech platforms, and government biodefense programs.
By merging biodefense preparedness with pharmaceutical innovation, Lunai Bioworks Inc. is building a dual-purpose transformer for safe generative biology. This positions the company as a category leader at the convergence of AI, healthcare, and security.
About Lunai Bioworks
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.
Acquisition expands agent-driven analytics and storytelling as GoodData advances enterprise data intelligence.
SAN FRANCISCO, CA / ACCESS Newswire / September 9, 2025 / GoodData, the AI-native analytics platform, today announced its acquisition of Understand Labs, a pioneer in data storytelling and agentic analytics experiences. This acquisition strengthens GoodData’s foundation for delivering explainable, human-centered, AI-driven insights and accelerates the company’s roadmap toward the next generation of enterprise intelligence.
Founded in 2021 by Peter Fedorocko, co-founder and former CTO of Stories.bi (later acquired by Workday), Understand Labs has been at the forefront of solving the critical “last mile” challenge in analytics: helping businesses not just see data, but truly understand it. Their flagship SDKs power custom data storytelling solutions for industries including e-commerce, retail, logistics, and media.
“We believe analytics must go beyond charts and dashboards to deliver real, actionable intelligence. By combining Understand Labs’ storytelling technology with GoodData’s AI-native platform, we’re accelerating the industry’s move toward agentic, explainable, and decision-driven analytics,” said Roman Stanek, Founder and CEO of GoodData. “This acquisition is an important step toward our vision of making AI a trusted, everyday partner for every business user.”
Through this acquisition, GoodData will enhance its platform, leading to faster insight-to-action for business teams and a broader adoption of AI across GoodData’s customer base. By leveraging Understand Labs’ expertise, GoodData will be able to:
Improve AI-generated narratives related to explainability, key drivers, and natural language engagement.
Accelerate integrating agentic workflows directly into dashboards and data experiences.
Provide new options for business users when it comes to guided decision-making and engagement points.
“Over the last six months, we’ve had the opportunity to collaborate with GoodData on several complex enterprise projects. It was incredible to see how GoodData’s developer-friendly, composable platform amplified our ability to deliver unconventional, agentic applications,” said Peter Fedorocko, Founder & CEO of Understand Labs, and now Field CTO at GoodData. “Joining forces allows us to combine our deep expertise in augmented analytics with GoodData’s robust platform, perfectly positioned for the upcoming era of enterprise intelligence.”
Looking Ahead
The acquisition accelerates GoodData’s roadmap by bringing agent-driven analytics and storytelling components to market faster. Customers will benefit from more powerful natural language experiences, including richer narratives, explainable recommendations, and advanced key driver analysis. And GoodData will continue to expand its agentic analytics capabilities throughout 2025, with an upcoming launch that will showcase the first wave of tailor-made, embedded AI agents.
About GoodData
GoodData is the AI-native analytics platform built for speed, scale, and trust, helping companies deliver real-time insights – embedded, branded, and everywhere your users need them.
Founded in 2007, and with offices in both the U.S. and Europe, GoodData serves over 140,000 of the world’s top companies and 3.2 million users, helping them drive meaningful change and maximize the value of their data.
VANCOUVER, BC / ACCESS Newswire / September 9, 2025 / 1933 Industries Inc. (the “Company” or “1933 Industries”) (CSE:TGIF)(OTCID:TGIFF), a Nevada-focused cannabis cultivator and producer, is pleased to announce that it has closed the previously announced (see news release dated September 2, 2025) Debenture Repurchase Agreement (the “Agreements”) with two arm’s length parties (together the “Vendors“), for the repurchase and cancellation of a portion of Company’s outstanding unsecured convertible debentures.
Pursuant to the Agreements, the Company repurchased $475,000 in principal value of debentures for a total cash consideration of $47,500 CAD. Following the closing, the debentures were transferred, cancelled and removed from the Company’s outstanding liabilities.
The Agreement was conducted in accordance with the provisions of the trust indenture dated December 31, 2023, applicable securities laws, and the policies of the Canadian Securities Exchange (the “CSE“).
About 1933 Industries Inc.
1933 Industries is a Nevada-based licensed producer, focused on the cultivation and extraction of a large portfolio of cannabis consumer products in a variety of formats under its flagship brands, Alternative Medicine Association (AMA) and Level X. Its product offerings are cultivated at the Company’s 68,000 sq. ft. indoor facility and marketed directly to retail dispensaries. AMA branded flower, infused pre-rolls, and in-house boutique concentrates consistently rank as the top products sold in Nevada. For more information, please visit www.1933industries.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. 1933 Industries undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Wednesday, September 17th, at 12:30pm at the Life Science Executive Partnering (“LSX”) World Congress 2025 in Boston, MA.
Event Information:
Event
NanoViricides Presentation at the LSX World Congress, 2025, Boston, MA
Day & Date
Wednesday, September 17, 2025
Time
12:30 pm
Location
LSX Biotech ShowCase (Day 2), Thomas Michael Menino (Boston) Convention and Exhibition Center, Boston, MA.
Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing.
Dr. Diwan has several pre-scheduled meetings in the partnering sessions and will also be available for meetings during the Congress on September 16th and 17th outside his busy schedule.
NanoViricides’ Current Antiviral Drugs Pipeline
The nanoviricides™ platform technology is yielding novel antiviral drug candidates against a number of challenging viral targets at a rapid pace.
Our most advanced candidate, NV-387, is an ultra-broad-spectrum antiviral with potential activity against most respiratory human pathogenic viruses – and more, because it emulates the attachment receptor family of sulfated proteoglycans that over 90% of human viruses utilize.
Moreover, NV-387 is designed to shape-shift upon binding to the virus particle, in the process disrupting the virus particle and making it incapable of infection, as a complete chemical nanomachine that destroys the virus.
The revolutionary broad antiviral spectrum of NV-387 is reminiscent of the dawn of antibiotics to combat bacterial infections.
Viruses are unlikely to escape NV-387 because no matter how much a virus evolves, it continues to utilize and require binding to sulfated proteoglycans – the very characteristic that NV-387 emulates. This solves the long-standing problem of antiviral medicines, that viruses escape them. Vaccines, antibodies and small chemical drugs are readily escaped by viruses as the viruses evolve in the field. This has been repeatedly observed during the recent COVID-19 pandemic, as well as in the course of most of the other viral epidemics including Influenza and HIV/AIDS.
Continued redevelopment or “updating” of vaccines necessitated by the viral escape or drift has recurrently cost billions of dollars every year for Influenza as well as COVID. NV-387 promises to make such costly endeavors unnecessary, once this drug is approved by regulatory bodies.
NV-387 is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation for the Treatment of MPOX disease, in response to the continuing Public Health Emergency of International Concern in WHO African Region. We already have received preliminary approval of the clinical protocol and the study and now we are working diligently to finish and submit the clinical trial application.
NV-387 was found to be highly effective against the “tripledemic” respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. NV-387 was found to be substantially superior to existing drugs, and even resulted in complete cure in the RSV animal study.
Further, NV-387 has shown excellent effectiveness in lethal lung infection animal models relevant for Smallpox and MPox viruses.
Additionally, NV-387 has shown excellent effectiveness in lethal lung infection in a humanized (hCD150+ knock-in) mouse model by the Measles virus. Cases of Measles have been rapidly rising in the developing world including USA, Canada, UK and European countries. Measles is an important health threat because the disease can lead to “immune amnesia”, wiping out pre-developed immunity against other diseases, because it attacks the immune system itself.
At present, there are no generally approved drugs for the treatment of RSV, MPox, or Measles. The latter two are orphan diseases in the USA and will be eligible for earning a “Priority Review Voucher” (PRV) from the US FDA plus several years of market exclusivity upon approval. Each PRV is currently thought to be worth $150 million to $350 million as a tradable asset.
Additionally, NV-387’s success in treating MPox is expected to make it feasible to achieve US FDA regulatory approval as a Smallpox therapeutic, a much-needed drug for the US Bioterrorism defense strategy, with potential lucrative US Government and International contracts for stockpiling in the range of several hundred millions of dollars, assuming NV-387 is successful in a Phase II clinical trial for MPox treatment.
The overall market size of NV-387 indications is estimated to be well in excess of $10 billion.
NV-387 is expected to become an “emperic therapy” for viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections.
NV-387 would be the first ever drug enabling emperic antiviral therapy, and would be potentially as revolutionary to antiviral therapy as antibiotics have been to anti-bacterial therapy. Emperic therapy means when the patient presents to the doctor, immediately the antiviral drug can be prescribed and started without having to wait for discriminating test results as to which virus is causing the infection. This has tremendous benefits since antiviral drugs are most effective when given as early as possible upon viral infection.
In addition, the Company has developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well.
The Company has also developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1.
NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code Specific Delivery
Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery.
Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work.
Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack.
Life Science Executive Partnering (LSX) World Congress will be held on Sept 16-17, with Forums on Sept 15, 2025, at the Thomas Michael Menino Convention & Exhibition Center, Boston, USA.
What is LSX World Congress-USA ? LSX World Congress-USA is where innovators, investors and senior life science dealmakers in the LSX community connect, learn and partner. The Congress gathers leaders from the US biotech, medtech, and pharmatech sectors to network, showcase innovations, and explore partnership opportunities. It offers a unique platform for CEOs, investors, and pharma executives to engage in meaningful discussions and collaborative sessions, shaping the future of healthcare technology. Empowering innovation, accelerating investment and facilitating partnering to shape the future of healthcare is the objective of LSX World Congress.
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.
New preclinical findings highlight Telomir-1’s ability to reverse CDKN2A gene silencing by DNA methylation, reactivating this gene – often called the body’s natural “cell cycle brake.” These results build on prior STAT1 data, supporting Telomir-1’s profile as a potential first-in-class broad-spectrum DNA methylation reset therapy.
MIAMI, FLORIDA / ACCESS Newswire / September 9, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company developing therapies that target the root causes of biological aging, cancer, and age-related diseases, today announced new preclinical cancer data showing that Telomir-1 reverses DNA methylation of CDKN2A, a master tumor suppressor gene silenced in many aggressive cancers.
Reactivating Cancer’s Brakes CDKN2A is one of the body’s most important natural defenses against cancer. Often called the “cell cycle brake,” this gene tells cells when to stop dividing and helps damaged cells self-destruct. In many cancers, CDKN2A is switched off by abnormal DNA methylation, leaving tumors free to grow unchecked. By resetting this methylation, Telomir-1 appears to turn the brake back on – restoring a critical safeguard that cancer cells had disabled.
Why DNA Methylation Matters DNA methylation is a key epigenetic process that controls whether genes are switched on or off. In healthy cells, methylation helps regulate normal development and repair. In cancer, however, abnormal DNA methylation can silence critical tumor suppressor genes like CDKN2A and STAT1, allowing tumors to grow unchecked and evade the immune system. Similarly, widespread changes in DNA methylation patterns are recognized as one of the hallmarks of aging, contributing to the loss of cellular function and the onset of age-related diseases.
By demonstrating the ability to reduce DNA methylation of these important targets, Telomir-1 is showing potential to directly address these fundamental biological processes. This positions Telomir-1 not only as a novel oncology candidate, but also as a potential first-in-class longevity drug candidate targeting the root causes of aging and disease.
In aggressive human prostate cancer cell models (PC3 xenografts), Telomir-1 inhibited CDKN2A DNA methylation more effectively than both Rapamycin and chemotherapy. These results complement Telomir’s previously reported data showing that Telomir-1 also resets STAT1, a master regulator of immune surveillance. Together, these findings suggest that Telomir-1 may broadly reverse cancer-induced silencing of key tumor suppressors – tackling two of cancer’s most fundamental escape mechanisms: unchecked growth and immune evasion.
CEO Perspective “This new evidence reinforces Telomir-1’s potential as a first-in-class longevity drug candidate that addresses the root causes of aging and age-related diseases through its ability to reset abnormal DNA methylation patterns,” said Erez Aminov, Chief Executive Officer of Telomir. “By demonstrating that Telomir-1 can reverse cancer-induced gene silencing in tumor suppressors such as CDKN2A and STAT1, we are beginning to show how epigenetic reprogramming may restore fundamental cellular functions that are disrupted in both cancer and aging.”
Scientific Perspective “These findings are highly significant,” said Dr. Itzchak Angel, Chief Scientific Advisor at Telomir. “By simultaneously reactivating STAT1 and CDKN2A, Telomir-1 demonstrates the ability to reset epigenetic silencing across multiple tumor suppressor pathways. This dual restoration of both immune surveillance and cell cycle control represents a powerful mechanistic advance in cancer epigenetics and provides a compelling rationale for further translational development.”
Advancing Toward the Clinic Telomir is actively assessing Telomir-1 across multiple aggressive cancers beyond prostate, with additional studies underway. The company’s pre-IND program is running in full gear, with CMC activities scaling up toward GMP production and IND-enabling studies ongoing as Telomir moves toward its first IND submission.
Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.
Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
